2023 ¼ºÀα޼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö : 2023-10-14
±³À°ÀÏÀÚ : 2023-10-14
±³À°Àå¼Ò : °æÁÖ È¹éÄÁº¥¼Ç¼¾ÅÍ
±³À°ÁÖÁ¦ : 2023 ¼ºÀα޼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¼Ò¾Æ±Þ¼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸
´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ : hematology@kams.or.kr
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀÎ : 50¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª : °æ»óºÏµµ
±³À°½Ã°£ : 4 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10¿ù 14ÀÏ 101 10:00~10:30 MRD(minimal residual disease) diagnostic technique in adult ALL(acute lymphoblastic leukemia) ÀÌÁö¼ö(¼¿ïÀÇ´ë )
±³À°½Ã°£ 10¿ù 14ÀÏ 101 10:30~11:00 MRD(minimal residual disease)-based treatment approach: real world experience Á¤Çظ²(¿¬¼¼ÀÇ´ë )
±³À°½Ã°£ 10¿ù 14ÀÏ 101 11:10~11:40 Recent advances in immunotherapy & CAR-T in ALL(acute lymphoblastic leukemia) À±ÀçÈ£(°¡Å縯ÀÇ´ë )
±³À°½Ã°£ 10¿ù 14ÀÏ 101 11:40~12:10 Optimal sequencing treatment for relapsed ALL(acute lymphoblastic leukemia ) ÀÌÁöÇö(µ¿¾ÆÀÇ´ë )
±³À°½Ã°£ 10¿ù 14ÀÏ 101 13:10~13:40 "Clinical impacts of the concomitant use of L-asparaginase and total parenteral nutrition in ALL(acute lymphoblastic leukemia) patients " °í¹Î¿À(¼¿ï´ë¾à)
±³À°½Ã°£ 10¿ù 14ÀÏ 101 13:40~14:10 Recent update of antibody-based chemotherapy in newly diagnosed adult ALL(acute lymphoblastic leukemia) ¹éµ¿¿ø(°æºÏÀÇ´ë )
±³À°½Ã°£ 10¿ù 14ÀÏ 101 14:10~14:40 CNS(central nervous system) Relapse in adult ALL(acute lymphoblastic leukemia) patients ÀÌÁ¾Çõ(°¡Å縯ÀÇ´ë )
±³À°½Ã°£ 10¿ù 14ÀÏ 101 15:00~15:30 "Phase II trial of Rituximab preconditioning for relapsed/refractory B-cell ALL treated with blinatumomab (RICOBAL) " º¯ÀÚ¹Î(¼¿ïÀÇ´ë )